Analysts think AGEN stock price could increase by 32%
Aug 26, 2024, 6:25 AM
-10.71%
What does AGEN do
Agenus, Inc., a clinical-stage company based in Lexington, Massachusetts, specializes in developing technologies to treat cancers and infectious diseases, employing 533 full-time staff. The company, public since 2000, focuses on immune system therapies, including botensilimab and balstilimab, and has multiple clinical trials underway.
6 analysts think AGEN stock price will increase by 32.12%. The current median analyst target is $7.65 compared to a current stock price of $5.79. The lowest analysts target is $6.06 and the highest analyst target is $18.90.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
